Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quoin Pharmaceuticals, Ltd. - American Depositary Shares (NQ: QNRX )

0.5500 +0.0600 (+12.24%)
Streaming Delayed Price Updated: 1:52 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quoin Pharmaceuticals, Ltd. - American Depositary Shares

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome
From Quoin Pharmaceuticals, Inc.
Via GlobeNewswire
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics
From PCG Digital
Via ACN Newswire
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Asensus Shares First Quarter Results and Future Plans
From PCG Digital
Via ACN Newswire
A Pivotal Year Ahead for Quoin Pharmaceuticals
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Quoin Pharmaceuticals: Strategically Building For Future Success
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug
LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received... 
From Skinvisible Inc
Via AccessWire
Exposures Product Safety
Quoin Pharmaceuticals Targeting Regulatory Approvals for Lead Candidate for Netherton Syndrome in 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Changing Lives, Delivering Value: Quoin Pharmaceuticals is Making the Balancing Act Look Easy
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Quoin Pharmaceuticals Poised for Rapid Commercialization of Promising Pipeline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.